Prosecution Insights
Last updated: May 29, 2026

Allergan Pharmaceuticals International Limited

7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
4
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (57%)
0
Easy (0%)
3
Unknown (43%)

Rejection Statute Mix

BucketCases
§103 only4 (57%)
No statute on record3 (43%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WEDDINGTON, KEVIN E 2 75.3% +9.9%
HELLMAN, KRISTINA M 1 66.0% +54.3%
MAEWALL, SNIGDHA 1 58.8% +9.7%
GAMETT, DANIEL C 1 67.6% +28.8%
MARTIN, PAUL C 1 42.0% +21.7%
CHONG, YONG SOO 1 43.7% +41.6%

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18359728 PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES HELLMAN, KRISTINA M 117d overdue
17998763 COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF GAMETT, DANIEL C 71d overdue
16433298 TREATMENT OF MIGRAINE CHONG, YONG SOO 71d overdue
16558488 HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS MARTIN, PAUL C 26d overdue

Top Art Units

Art UnitApps
1629 2
1654 1
1612 1
1647 1
1653 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19055912 METHODS OF TREATING MIGRAINE WEDDINGTON, KEVIN E 1629 §103 Non-Final OA 66d overdue Pending Feb 18, 2025
18913492 METHODS OF TREATING MIGRAINE WEDDINGTON, KEVIN E 1629 §103 Non-Final OA 2d overdue Pending Oct 11, 2024
18359728 PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES HELLMAN, KRISTINA M 1654 Other Non-Final OA 117d overdue Pending Jul 26, 2023
18215098 DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATION MAEWALL, SNIGDHA 1612 Other Final Rejection 99d overdue Pending Jun 27, 2023
17998763 COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF GAMETT, DANIEL C 1647 §103 Final Rejection 71d overdue Pending Nov 14, 2022
16558488 HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS MARTIN, PAUL C 1653 Other Non-Final OA 26d overdue Pending Sep 03, 2019
16433298 TREATMENT OF MIGRAINE CHONG, YONG SOO 1623 §103 Final Rejection 71d overdue Pending Jun 06, 2019

Managing Allergan Pharmaceuticals International Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month